Market Intelligence, Clinical Progress, and High-Purity Reagents for Gout & Hyperuricemia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for URAT1/SLC22A12 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (Primary) | URAT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for 12-TM protein conformation. |
View URAT1 Products |
| Antigen | URAT1/SLC22A12 Full-Length Membrane Preparation HEK293 Overexpression System. Sequence Verified, Endotoxin Controlled. |
View URAT1 Products |
| Benchmark Ab | Anti-URAT1 Rabbit Recombinant mAb (Clone SLC12-1) For Western Blot, Flow Cytometry, and IHC validation. Sequence Verified. |
View URAT1 Products |
| Validator | URAT1/SLC22A12 siRNA Set Three unique duplexes for knockdown verification in urate uptake assays. |
View URAT1 Products |
| Related Target A | SLC2A9 (GLUT9) Synergistic urate reabsorption transporter in the proximal tubule; co-target for combination strategies. |
View SLC2A9 Products |
| Related Target B | SLC22A6 (OAT1) Renal organic anion transporter; essential off-target selectivity counter-screen for nephrotoxicity avoidance. |
View SLC22A6 Products |
| Related Target C | ABCG2 (BCRP) Compensatory urate efflux transporter; resistance mechanism analysis. |
View ABCG2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformation for functional uptake assay | Full-length URAT1 Lentivirus & Stable Cell Lines (HEK293 background); preserves 12-TM topology for physiological relevance |
| Cross-species cyno/mouse eval | Human / Cyno / Mouse URAT1 ortholog ORF clones available; Sequence Verified for translational PK/PD |
| SLC22 subfamily counter-screening | Homolog panel cell lines (OAT1, OAT3, OAT4) strictly verified by mass spec for selectivity profiling |
| Lack of Controls | Target-Specific Reference Standards & Positive Control Lysates included |
| False Positives | Validated siRNA included for target-specificity confirmation in urate uptake assays |
Live URAT1/SLC22A12 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for URAT1-targeted therapeutics has entered a new phase following the withdrawal of first-generation inhibitors (e.g., Lesinurad) due to renal safety concerns. Major players are now advancing next-generation inhibitors with improved selectivity profiles over OAT transporters. As Dotinurad gains traction in Asian markets and Verinurad advances through Phase II/III, the competitive focus has shifted from pure potency to safety margins and combination potential with XO inhibitors. The next wave of R&D is targeting novel allosteric sites and tissue-specific delivery to minimize renal off-target effects, alongside biomarker-driven patient stratification to identify responders with specific URAT1 polymorphisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (2nd Gen) | Fuji Yakuhin (Dotinurad), AstraZeneca (Verinurad), Hengrui (SHR-4640) | Gout, Tumor Lysis Syndrome, CKD-associated Hyperuricemia | Uptake Inhibition Assay (Need high-expression stable cell lines with verified membrane localization) |
| Dual-Inhibitor (URAT1/XO) | RLS (Xian) Tech, Shionogi | Refractory Gout | Selectivity Screening (Need URAT1 and XO matched reagents) |
| PROTAC / Degraders | Emerging Biotechs | Severe Hyperuricemia | Degradation Tracking (Need Anti-URAT1 antibodies for Flow/WB) |
Key Mutations & Genetic Variants
- rs12800450: Reduced urate transport; uncertain significance (UniProt Q96S37 VAR_036720).
- RHUC1-associated variant: Strongly reduced urate transport; dbSNP:rs121907896 (UniProt Q96S37 VAR_036721).
- RHUC1-associated variant: Reduced urate transport; decreased localization (UniProt Q96S37 VAR_084699).